Abstract The key processes of lung development have been elucidated in the past several decades, helping to identify and characterize the resident progenitor cells that ultimately generate the mature organ. The adult lung is a complex organ consisting in scores of different cell lineages that are remarkably quiescent in the absence of injury. Despite low cellular turnover, the lung can respond quickly and dramatically to acute damage, with spatially restricted stem and progenitor cells re-entering the cell cycle and differentiating to promote repair. The findings from lung developmental biology are now being used to examine the mechanisms that underlie lung regeneration. The use of in vitro models such as pluripotent stem cells and new methods of gene editing have provided models for understanding lung disease and exploring the mechanisms of lung regeneration and have raised the prospect of correcting lung dysfunction. We outline the way that basic studies into lung developmental biology are now being applied to lung regeneration, opening up new avenues of research that may ultimately be harnessed for treatments of lung disease.
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Development of the lung
Discussion of lung regeneration or disease modeling requires a thorough understanding of the way that the lung is generated during normal development. Much of what is known about lung development comes from the extensive studies performed during the last two decades of research on mouse lung development. Whereas differences exist between the mouse and human lung, the power of the mouse genetic model remains pre-eminent when examining the basics of lung development. The development of the mammalian lung can be broken down into three phases: (1) early specification of lung endoderm and mesoderm progenitors within the anterior foregut including the initial outpouching of the endoderm tube that generates the lungs, (2) branching morphogenesis that arborizes this primitive lung tube in a highly stereotypical manner that generates hundreds to thousands of branch tips, (3) sacculation and alveolarization, in the last phase of lung development, which generates the functional gas exchange units required for postnatal respiration (Morrisey and Hogan 2010; Fig. 1) .
Lung development initiates when the ventral side of the anterior foregut endoderm is specified for the lung endoderm fate, which is noted by the expression of the transcription factor Nkx2.1 (Cardoso and Lu 2006) . In mice, this specification event happens at approximately embryonic day 9 (E9.0). The specified lung endoderm (Nkx2.1+) evaginates from the ventral side of the anterior foregut endoderm at approximately E9.5 in the mouse and forms two primitive lung buds. These buds are progressively surrounded by mesenchyme and begin to branch. At the leading tips of the primary lung buds, a process of proximal-distal patterning of the endoderm begins and is denoted by the differential expression of the transcription factor Sox2, which demarcates the proximal portion of the branching lung epithelium and of Sox9 and Id2, which demarcate the most distal tips of the branching epithelium. The Sox2+ progenitors will generate all of the epithelial lineages within the conducting airways, including secretory cells, multi-ciliated cells and basal cells. The Sox9+/Id2+ cells are initially multipotent, capable of generating both airway and alveolar epithelium ). However, after E13.5, Sox9+ progenitors are restricted in their fate and only generate alveolar type 1 (AT1) and type 2 (AT2) cells. These studies have elucidated a model of progressive loss of the fate potential in lung endoderm progenitors based on the functional regions of this large and complex organ. This point will become important later when the various modes of lung regeneration are discussed.
Towards late gestation, the differentiation of distal Sox9+/ Id2+ progenitors into AT1 and AT2 cells is an important step in the process of generating functional alveolar gas exchange units. Recent evidence suggests the presence of a bipotent progenitor capable of equal differentiation into either AT1 or AT2 cells (Desai et al. 2014) . This bipotent progenitor is thought to exist in late gestation and early alveologenesis in the mouse (E18-P0) and has been proposed to be responsible for the generation of the lung alveolus. Specific markers for this bipotent progenitor remain unknown but further characterization of its potential and the pathways regulating its behavior will be important for understanding its full contribution towards generating a functional lung alveolus.
The Sox2+ progenitors give rise to the full complement of airway epithelial lineages. Whereas many of these lineages are fully differentiated functional cells, such as multi-ciliated cells and most secretory cells, several progenitor lineages are also produced during lung development from the Sox2+ early endoderm progenitors. These include basal cells, which express Trp63, Krt5 and Pdpn and generate multi-ciliated cells and secretory cells after airway injury in the adult trachea and main stem bronchi (Rock et al. 2009 ). Development of the airway epithelium is regulated by Notch signaling, which plays a key role in promoting secretory epithelial differentiation while inhibiting the differentiation of the multi-ciliated epithelium (Tsao et al. 2009) . A subset of secretory cells can also be found that self-renew and differentiate into multi-ciliated cells after injury (Hong et al. 2001; Giangreco et al. 2002) . In addition to these lineages, Sox2+ cells also generate pulmonary neuroendocrine cells, which play an important role in regulating the postnatal immune response in the lung (Branchfield et al. 2016) .
Developmental pathways in lung regeneration
Regeneration of the lung after acute injury involves multiple stem/progenitor lineages and thus, this process can be thought of as following a Bdemocratic principle^depending on the spatial niches involved (Kotton and Morrisey 2014 ). The Fig. 1 Progenitors of the lung throughout development. Throughout development, pluripotent cells remain present though to a decreasing capacity for differentiation. a The earliest lung-specified progenitors are the Nkx2.1+ endoderm cells found on the ventral side of the anterior foregut endoderm. b These endodermal progenitors (Nkx2.1+) then quickly undergo specification for either the proximal airway epithelium (Sox2+) or distal airway epithelium (Sox9+). c Following branching morphogenesis, namely after E13.5 in the mouse, the distal progenitors (Sox9+, Id2+, BMP4+, SPC+) are restricted and generate either AT1 and AT2 cells. d In the fully developed adult lung, multipotent progenitors exist in specific niches across the pulmonary epithelial tree including basal cells, variant Club or secretory cells, bronchioalveolar stem cells (BASCs) and alveolar type 2 (AT2) cells signaling pathways used by these progenitors are often the same as those used for the development of the lung (Shi et al. 2009; Whitsett et al. 2011; Herriges and Morrisey 2014; Akram et al. 2016; Bertoncello 2016) . In the large airways and trachea, activation of Trp63+ basal cells and their subsequent differentiation into secretory and multi-ciliated epithelial cells are regulated by a complex interplay of Notch signaling, mirroring the role that this pathway regulated in airway epithelial development (Guseh et al. 2009; Rock et al. 2011b; Tsao et al. 2011; Mori et al. 2015) . Variations of Notch have effects on a region stretching from the conducting airways, where Notch-3 suppresses basal cell over-expansion (Pardo-Saganta et al. 2015) , down to the alveoli where Notch-2 activation is necessary for alveologenesis (Tsao et al. 2016) . Recent work has also demonstrated unique plasticity in certain lung airway epithelial cells, with secretory cells exhibiting dedifferentiation backwards into basal cells to replenish the basal cell population after extensive injury (Tata et al. 2013) . The extent to which this plasticity has a role in physiological regeneration and the molecular pathways that regulate it are important topics that warrant further investigation.
In the more distal lung airways, Wnt signaling has been shown to be important for the expansion of a bronchioalveolar stem cell (BASC) lineage and this process is regulated by Gata6, a key transcription factor in lung development (Zhang et al. 2008 ). BASC differentiation is also regulated by BMP4 expression, which promotes TSP-1 expression in the lung endothelium; this TSP-1 in turn regulates the differentiation of BASCs (Lee et al. 2014) . These developmentally conserved signaling pathways during regeneration are not limited to the epithelium but are also seen in the supporting mesenchymal lineages. Hedgehog signaling in the adult lung maintains mesenchymal quiescence and inhibition of hedgehog can lead to increased epithelial proliferation at homeostasis and after injury (Peng et al. 2015) .
Modeling lung disease and regeneration
Multiple models are available in which to study lung disease processes and regeneration, including both in vivo and in vitro models. The primary in vivo model for the study of lung regeneration is the mouse. Whereas important cellular and physiological differences exist between the mouse and human lung, most if not all of the major cell lineages are shared and, from emerging human lung studies, the expression and function of many of the major transcriptional and signaling pathways are conserved. Importantly, the identification of these major regulators of lung development and regeneration in the mouse system has enabled exciting new investigations to be carried out in the human system through the derivation of human lung epithelial cells including AT2 cells from pluripotent stem cells and the use of primary human lung cells in lung organoid culturing systems (Rock et al. 2009 (Rock et al. , 2011b Longmire et al. 2012; Mou et al. 2012; Barkauskas et al. 2013) . In addition to these assay systems, emerging techniques in bioengineered systems such as lung-on-a-chip allow the assessment of cell-cell and cell-matrix interactions in a higher throughput manner (Fig. 2) .
In vivo animal models
Given the complexity of the lung and highly heterogeneous cell lineage composition, the use of an in vivo system to study lung disease modeling and tissue regeneration remains the gold standard. The genetic power of the mouse makes it the pre-eminent in vivo model system to date for lung development and regenerative studies. The mouse has also proven to be an excellent model for the assessment of drug efficacy, pharmacodynamics and pharmacokinetic and toxicological profiles of novel interventions in the context of the entire body; such tests serve as essential precursors to clinical trials for lung disease treatments (Mercer et al. 2015) . Despite its usefulness, the modeling of human lung disease and lung regeneration in the mouse is significantly limited, as outlined below. The various mouse models of lung disease and regeneration do a good job of elucidating general cellular behaviors in disease and states of injury but are incapable of reflecting all aspects of the human condition.
A model of allergic asthma, which is induced by intertracheal exposure to ovalbumin, can reproduce some features of human asthma, such as increased lung eosinophils but does not give robust lung function responses (Kumar and Foster 2012) . The Aspergillus fumigatus model, however, induces significant amounts of serum IgE, airway hypereactivity, lung inflammation and a cytokine response (i.e., IL-4, Il-5) mimicking the human response to this allergic fungi (Haczku et al. 2001; Kurup and Grunig 2002) . Most current models of chronic obstructive pulmonary disease (COPD) are designed to induce emphysema and rarely mimic the disease of the small airways, bronchitis, or exacerbations (Mercer et al. 2015) . Fibrosis is most commonly modeled through the administration of the drug bleomycin. Whereas a single intertracheal dose in the mouse reproduces some aspects of bleomycin toxicity in humans, it lacks the persistent fibrotic expansion observed in people (Degryse and Lawson 2011) . Other delivery modes for bleomycin, including repetitive interperitoneal injections over the course of several weeks, may prove to mimic the human response to this drug better than the single intertracheal route (Peng et al. 2015) . In contrast, a mouse model of influenza-instigated acute lung injury does mimic many aspects of human influenza infection including the robust immune response and the development of keratin-5-expressing epithelium in the alveolar airspaces (Kumar et al. 2011; Vaughan et al. 2015; Zuo et al. 2015 ).
These models can provide critical information regarding the response of the lung to acute injury by delineating the regenerative cell lineages including various progenitor lineages. The knowledge gained from these in vivo models can be translated to biomimetic in vitro models of repair and regeneration.
Organoid model systems
In vitro models such as organoids have been employed to help provide alternatives to this research and have the beneficial utility of being applicable to the development of chronic disease modeling of the lung. Organoids can be generated from multiple cell types and generally self-aggregate into threedimensional structures that can mimic the organization of the native organ (Rock et al. 2009; Sato et al. 2009; Barker et al. 2010; Barkauskas et al. 2013; Nadkarni et al. 2016 ). In the lung, the source of cells used in organoids can include primary cells from human or mouse lungs or cells derived from differentiated pluripotent stem cells. To date, organoids have been generated from at least four distinct regions of the lung: trachea/bronchus (Rock et al. 2009 ), bronchioles (Vaughan et al. 2006; Peng et al. 2015) , bronchioalveolar duct junction (Kim et al. 2005 ) and the alveolus (Barkauskas et al. 2013) . Organoid formation from various lung progenitor lineages allows the examination of factors required for both selfrenewal and differentiation. For example, Barkauskas et al. (2013) showed that primary AT2s, when cultured as organoids called alveolospheres, generate both AT2 and AT1 cells. Similarly, Lee et al. (2014) demonstrated that BASCs can generate AT1s and AT2s and, in the presence of pulmonary endothelial cells, can form organoids representative of the bronchiolar, bronchioalveolar and alveolar regions in vitro.
Organoid assay systems can also be used to model human diseases, including those that affect the lung such as cystic fibrosis. Forskolin-induced swelling of organoids caused by defects in the Cftr gene can be modeled in human intestinederived organoid cultures (Dekkers et al. 2013 ). Importantly, this defect can be corrected by using CRISPR/Cas9-mediated gene editing (Dekkers et al. 2013) . Similarly, the use of human bronchospheres to study goblet cell metaplasia has resulted in the discovery of the Notch pathway being a potential therapeutic target for the disease (Danahay et al. 2015) . In the future, organoid culture assays should be able to identify Fig. 2 Options for cell behavior and disease modeling in the lung. Since no perfect assays exist to model all aspects of cell behavior or disease states in the lung, a combination of approaches will be the most efficacious. The in vivo mouse model remains the gold-standard for nearly all aspects of cell and developmental biology and of disease modeling because of its wide accessibility and the power of mouse genetics. Organoids derived from region-specific cells (e.g., basal, AT2s, etc.) allow assays on specific progenitors of the lung. Patient-derived induced pluripotent stem cells (iPSCs) have shown promise in their ability to be used in various models described here. Recent biomimetic devices such as the lung-on-a-chip allow for an analysis of cell-cell interactions that can be perturbed by physiologic cues (i.e., shear stress and stretch). Tissue engineering is being applied to create tissue orthologs that can be tested in vitro to improve our understanding of cell-matrix interactions proliferative cues for human adult lung progenitors and to assess their ability to differentiate into various daughter cell lineages. Variables including the inclusion of distinct mesenchymal lineages, vascular endothelial lineages and other cell types will help reveal the cell-cell and cell-matrix interactions required for the self-renewal and differentiation of these progenitors.
Bioengineered models
The lung-on-a-chip, a subset of organ-on-a-chip microfluidic devices, is a bioengineered device that is based on modeling cell-cell interactions that can be explored pharmacologically. The lung-on-a-chip devices are meant to supplement more traditional cell culture approaches, such as the air-liquid interface (ALI; Bals et al. 2004) , that lack aspects of the in vivo scenario (e.g., shear stress, stretch, etc.), while also keeping the cells in a three-dimensional environment that can be monitored in real-time and networked with other organ chips (Esch et al. 2011) . Through the use of computational fluid dynamics, the chips can be employed to mimic pulmonary capillary gas exchange by controlling the partial pressures of oxygen on the arterial and venous ends of the system (Long et al. 2012 ). The two major compartments of the lung, namely the conducting airways and the alveoli, have both been modeled thus far and challenged with certain physiological stimuli such as plug rupture and inflammatory insult (Huh et al. 2007 (Huh et al. , 2010 . More importantly, certain physiologic responses have been correlated to in vivo rodent models, such as IL-2-induced pulmonary edema with rescue by angiopoietin-1 administration (Huh et al. 2012 ). To date, there has been a dearth of reports involving primary human cells in these devices, whether directly from harvested organs or derived from pluripotent stem cells. These cell types and the inclusion of other lineages, such as the diverse array of mesenchymal lineages, will need to be included in future studies to validate the importance of this model.
An additional in vitro bioengineered lung model is the decellularized tissue system in which cells are removed by using a combination of detergents to leave behind a rigid extracellular matrix that can be subsequently used for reseeding with pulmonary-derived cells (Balestrini et al. 2016) . Using this technique, the unique architecture of the lungs, with bifurcating networks of airways and blood vessels, can be maintained following the removal of the living cellular component . Whereas several studies have employed this model to reseed lung cell lineages including endothelial cells and some epithelial lineages (Ren et al. 2015; Stabler et al. 2016) , most cells do not survive in culture long term (i.e., >2 weeks) and in the case of epithelial cells, many de-differentiate probably because of the absence of a complete repertoire of niche signals (Calle et al. 2015) .
Pluripotent stem cells
The advent of induced pluripotent stem cells (iPSC) has provided exciting opportunities to assess the capacity of human lung progenitor cells for self-renewal and differentiation (Takahashi and Yamanaka 2006) . In general, the generation of endodermal derivatives, such as lung epithelium, from embryonic stem cells (ESCs) and iPSCs has been more difficult than from mesodermal and neural cell lineages. Recent studies have now shown that ESCs and iPSCs can be differentiated into lung epithelial cell lineages, including both the Sftpc+ AT2s and Scgb1a1+ secretory cell lineages (Longmire et al. 2012; Mou et al. 2012; Huang et al. 2013 ). The protocols used for differentiating lung epithelial lineages have utilized multiple signaling pathways critical for lung development including Wnt, Bmp and Fgf. As with many iPSC-induced differentiation protocols, the precise temporal application of signaling activators and inhibitors is necessary to promote lung epithelial cell differentiation ). The greatest hurdle in the study of ESC-or iPSC-derived lung epithelium is that the resulting cells are immature and do not represent a fully functional differentiated cell. Despite this and other limitations, such differentiation protocols have been used in various models to explore the differentiation potential of human and mouse ESCs and iPSCs, including the kidney capsule formation assay Liu et al. 2014 ), lung-on-a-chip type models such as ALI culture (Wong et al. 2012; Firth et al. 2014 ) and bioengineered models such as culture within the decellularized lung (Longmire et al. 2012) . The major benefit of patient-derived iPSCs is their capacity to harbor genetic mutations that affect respiratory function such as cystic fibrosis or alpha-1 anti-trypsin deficiency. Wong et al. (2012) showed that differentiated airway epithelium from iPSCs derived from a human patient with cystic fibrosis exhibited aspects of the cystic fibrosis phenotype that could be rescued following treatment with the small molecule C18 in an ALI culture. With the establishment of human biobanks containing hundreds of patient-derived iPSCs from lung diseases (Somers et al. 2010) , this technology will only become more useful in the future for screening therapies for lung disease treatments.
Promoting adult lung regeneration Developmental pathways and adult lung regeneration
Multiple developmental pathways have been demonstrated to have an important regulatory function in lung regeneration assays. Wnt signaling is a critical pathway in lung endoderm specification and the absence of Wnt signaling leads to complete lung agenesis (Goss et al. 2009; Harris-Johnson et al. 2009 ). Wnt signaling is re-activated in the adult lung after injury and during repair and regeneration (Zhang et al. 2008; Flozak et al. 2010; Al Alam et al. 2011; Hashimoto et al. 2012; Aumiller et al. 2013 ). Wnt signaling is activated upon naphthalene-induced airway injury and ectopic activation of Wnt signaling caused by deletion of the transcription factor Gata6 leads to the expansion of BASCs (Zhang et al. 2008) . Interestingly, the pharmacological inhibition of Wnt signaling reduces bleomycin-induced fibrosis in mice suggesting that Wnt signaling can also be used to block this deleterious response to injury (Henderson et al. 2010) . Thus, the ability of Wnt signaling to promote proper repair and regeneration after injury is context-dependent and chronic activation could lead to increased fibrosis.
The Notch signaling pathway plays a critical role in promoting secretory cell differentiation during lung endoderm development (Guseh et al. 2009; Tsao et al. 2009 ). Interestingly, this function of Notch is recapitulated after airway injury and controls basal cell differentiation. Thus, activation of Notch could be used to expand the secretory lineage after airway injury (Rock et al. 2011a; Xing et al. 2012 ). However, this would come at the expense of decreased multi-ciliated epithelial differentiation, which would result in an imbalance of differentiated cell types in the repaired airway.
Epigenetic regulation by histone acetylation and histone deacetylation has been associated with adult lung diseases including asthma and COPD. Histone acetylation is regulated by multiple enzymes within the histone acetyltransferase (HAT) and histone deacetylase (HDAC) protein families. Asthma patients exhibit increased HAT activity and decreased HDAC activity in their airway epithelium (Gunawardhana et al. 2014) . In COPD patients, a correlation has been demonstrated between disease severity and progression and decreased HDAC2 expression (Ito et al. 2005) . Genetic knockout models of histone deacetylase (HDAC) deficiency are starting to be used to address the effects of HDACs in lung regeneration. Loss of HDAC1/2 in the postnatal lung secretory epithelium results in the increased expression of tumor suppressors including Rb1, p21/Cdkn1a and p16/Ink4a after injury (Wang et al. 2013) . This results in a loss of cell proliferation, which is required for secretory cell regeneration. HDAC2 also plays an important role in regulating the expression of the cytokine IL-6, which is important for inhibiting the alveolar response to hyperoxic lung injury (Chokas et al. 2010 ).
Cell and gene therapies for lung disease and regeneration
The application of adult stem/progenitor cells or patient-derived iPSCs for treatments of pulmonary disease is an attractive extension of the basics of developmental biology towards new therapeutic approaches to lung disease. Other cellular options, such as mesenchymal stromal/stem cells, have not demonstrated efficacy beyond a small anti-inflammatory paracrine affect (Stabler et al. 2015; Ikonomou et al. 2016; McIntyre et al. 2016) . In contrast, the use of iPSCs to generate lung cell lineages for the replacement of cells following acute injury or disease-related loss might eventually be used for regenerative purposes. However, at the current time, no acceptable methods are available for the exogenous replacement of any lung cell type. Further research is needed on this topic, including the development of a robust engraftment assay that can be used to assess the feasibility of cell therapy in the lung. The architectural complexity of the respiratory system will probably continue to be a barrier to the development of such an assay.
Recent developments in gene editing could one day be used to correct monogenic mutations that cause lung disease. Advances in the use of CRISPR/Cas9 gene editing techniques could lead to the correction of lung diseases such as cystic fibrosis and α1-antitrypsin disorders. Of note, a team of Chinese scientists has received approval for the first use of CRISPR-Cas9 to modify T-cells in order to treat metastatic non-small cell lung cancer (Cyranoski 2016) . In this application, the patient's T cells are modified ex vivo and then retransplanted, a route of treatment that is unlikely to be useful in the lung in the near future. Despite the promise of CRISPR/ Cas9 in the correction of monogenic diseases, many adult lung diseases are probably polygenic and will require a better understanding of their genetic underpinning before gene editing can be applied to their treatment.
Summary and concluding remarks
The study of basic lung development has been crucial for understanding and manipulating the remodeling and regeneration of the adult organ. Whereas the mouse remains a workhorse for further understanding lung development and regeneration, the emergence of new model systems, including lung organoids and patient specific iPSCs, provides new means by which to study human lung biology. The future development of gene editing techniques and robust engraftment assays should further accelerate research into novel therapeutic approaches for lung disease and injury.
